These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 25105564)

  • 1. Structural basis of nSH2 regulation and lipid binding in PI3Kα.
    Miller MS; Schmidt-Kittler O; Bolduc DM; Brower ET; Chaves-Moreira D; Allaire M; Kinzler KW; Jennings IG; Thompson PE; Cole PA; Amzel LM; Vogelstein B; Gabelli SB
    Oncotarget; 2014 Jul; 5(14):5198-208. PubMed ID: 25105564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of the p85/p110alpha phosphatidylinositol 3'-kinase. Distinct roles for the n-terminal and c-terminal SH2 domains.
    Yu J; Wjasow C; Backer JM
    J Biol Chem; 1998 Nov; 273(46):30199-203. PubMed ID: 9804776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation loop sequences confer substrate specificity to phosphoinositide 3-kinase alpha (PI3Kalpha ). Functions of lipid kinase-deficient PI3Kalpha in signaling.
    Pirola L; Zvelebil MJ; Bulgarelli-Leva G; Van Obberghen E; Waterfield MD; Wymann MP
    J Biol Chem; 2001 Jun; 276(24):21544-54. PubMed ID: 11278889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineering of an isolated p110α subunit of PI3Kα permits crystallization and provides a platform for structure-based drug design.
    Chen P; Deng YL; Bergqvist S; Falk MD; Liu W; Timofeevski S; Brooun A
    Protein Sci; 2014 Oct; 23(10):1332-40. PubMed ID: 25043846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of constitutive phosphoinositide 3-kinase activation by oncogenic mutants of the p85 regulatory subunit.
    Shekar SC; Wu H; Fu Z; Yip SC; Nagajyothi ; Cahill SM; Girvin ME; Backer JM
    J Biol Chem; 2005 Jul; 280(30):27850-5. PubMed ID: 15932879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncogenic mutations weaken the interactions that stabilize the p110α-p85α heterodimer in phosphatidylinositol 3-kinase α.
    Echeverria I; Liu Y; Gabelli SB; Amzel LM
    FEBS J; 2015 Sep; 282(18):3528-42. PubMed ID: 26122737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A biochemical mechanism for the oncogenic potential of the p110beta catalytic subunit of phosphoinositide 3-kinase.
    Dbouk HA; Pang H; Fiser A; Backer JM
    Proc Natl Acad Sci U S A; 2010 Nov; 107(46):19897-902. PubMed ID: 21030680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calmodulin (CaM) Activates PI3Kα by Targeting the "Soft" CaM-Binding Motifs in Both the nSH2 and cSH2 Domains of p85α.
    Zhang M; Li Z; Wang G; Jang H; Sacks DB; Zhang J; Gaponenko V; Nussinov R
    J Phys Chem B; 2018 Dec; 122(49):11137-11146. PubMed ID: 30047727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A frequent kinase domain mutation that changes the interaction between PI3Kalpha and the membrane.
    Mandelker D; Gabelli SB; Schmidt-Kittler O; Zhu J; Cheong I; Huang CH; Kinzler KW; Vogelstein B; Amzel LM
    Proc Natl Acad Sci U S A; 2009 Oct; 106(40):16996-7001. PubMed ID: 19805105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.
    Hon WC; Berndt A; Williams RL
    Oncogene; 2012 Aug; 31(32):3655-66. PubMed ID: 22120714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural insights into the activation mechanism of phosphoinositide 3-kinase alpha.
    Jani V; Sonavane U; Sawant S
    Comput Biol Chem; 2024 Feb; 108():107994. PubMed ID: 38043374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of Class IA PI 3-kinases: C2 domain-iSH2 domain contacts inhibit p85/p110alpha and are disrupted in oncogenic p85 mutants.
    Wu H; Shekar SC; Flinn RJ; El-Sibai M; Jaiswal BS; Sen KI; Janakiraman V; Seshagiri S; Gerfen GJ; Girvin ME; Backer JM
    Proc Natl Acad Sci U S A; 2009 Dec; 106(48):20258-63. PubMed ID: 19915146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphorylated Calmodulin Promotes PI3K Activation by Binding to the SH
    Zhang M; Jang H; Gaponenko V; Nussinov R
    Biophys J; 2017 Nov; 113(9):1956-1967. PubMed ID: 29117520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of PI3Kα by physiological effectors and by oncogenic mutations: structural and dynamic effects.
    Gabelli SB; Echeverria I; Alexander M; Duong-Ly KC; Chaves-Moreira D; Brower ET; Vogelstein B; Amzel LM
    Biophys Rev; 2014 Mar; 6(1):89-95. PubMed ID: 25309634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allosteric Activation of PI3Kα Results in Dynamic Access to Catalytically Competent Conformations.
    Chakrabarti M; Gabelli SB; Amzel LM
    Structure; 2020 Apr; 28(4):465-474.e5. PubMed ID: 32049032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cryo-EM structures of PI3Kα reveal conformational changes during inhibition and activation.
    Liu X; Yang S; Hart JR; Xu Y; Zou X; Zhang H; Zhou Q; Xia T; Zhang Y; Yang D; Wang MW; Vogt PK
    Proc Natl Acad Sci U S A; 2021 Nov; 118(45):. PubMed ID: 34725156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The structure of p85ni in class IA phosphoinositide 3-kinase exhibits interdomain disorder.
    Sen KI; Wu H; Backer JM; Gerfen GJ
    Biochemistry; 2010 Mar; 49(10):2159-66. PubMed ID: 20131869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The iSH2 domain of PI 3-kinase is a rigid tether for p110 and not a conformational switch.
    Fu Z; Aronoff-Spencer E; Wu H; Gerfen GJ; Backer JM
    Arch Biochem Biophys; 2004 Dec; 432(2):244-51. PubMed ID: 15542063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110α (PIK3CA).
    Burke JE; Perisic O; Masson GR; Vadas O; Williams RL
    Proc Natl Acad Sci U S A; 2012 Sep; 109(38):15259-64. PubMed ID: 22949682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural Features that Distinguish Inactive and Active PI3K Lipid Kinases.
    Zhang M; Jang H; Nussinov R
    J Mol Biol; 2020 Nov; 432(22):5849-5859. PubMed ID: 32918948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.